HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites wiki
 

Celgene NEWS

NFE/5.0en-USnews-webmaster@google.com2019 Google Inc.Thu, 14 Feb 2019 03:27:31 GMTGoogle News
BMS can breathe easier now: Celgene's Revlimid has escaped a big patent challenge  FiercePharma

When Bristol-Myers Squibb picked up Celgene in one of biopharma's biggest deals ever last month, investors tagged one big risk: Celgene's megablockbuster ...

FiercePharma
Celgene Stock Rises After US Officials Decline Dr. Reddy's Revlimid Challenge  Investor's Business Daily

Celgene stock and Dr. Reddy's stock diverged Monday after U.S. officials declined to move forward with a patent challenge for cancer drug Revlimid.

Investor's Business Daily
Celgene vs. Gilead Stock: What’s the Better Biotech Buy?  Investorplace.com

Gilead stock has been stagnating, but there are other choices for investors. How about considering Celgene over GILD stock?

Investorplace.com
Celgene Doesn't Need Bristol-Myers  Seeking Alpha

A hedge fund potentially agitating for blocking the acquisition by Bristol-Myers adds risk to the short-term story. A $2.2 billion breakup fee reduces the risk.

Seeking Alpha
The Results Are In, and It's Clear Celgene Doesn't Need Bristol-Myers Squibb  Motley Fool

Both drugmakers have reported their Q4 results and provided guidance for 2019. And Celgene isn't just doing fine on its own: It's beating Bristol-Myers Squibb.

Motley Fool
Why Celgene Corporation (CELG) Has Been Blazing Hot?  The RNS Daily

Celgene Corporation (NASDAQ:CELG) stock enjoyed an overall uptrend of 38.99% from the beginning of 2019. The closing share price quoted for February 12, ...

The RNS Daily
For BeiGene, Bristol-Celgene deal is poised to have big ripple effects  STAT

SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month's ...

STAT
Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?  Yahoo Finance

Celgene Corporation CELG is likely to beat expectations when it reports fourth-quarter results on Jan 31, before the opening bell. In the last reported quarter, the ...

Yahoo Finance
Celgene Corp.: Determining The Fair Value For Its Stock  Seeking Alpha

Celgene currently (01/15/2019) trades for $88.2 which signals uncertainty among investors. The fair value for the combined company and thus for Celgene's ...

Seeking Alpha
O Dell Group LLC Trims Stake in Celgene Co. (NASDAQ:CELG)  Fairfield Current

O Dell Group LLC reduced its stake in shares of Celgene Co. (NASDAQ:CELG) by 5.7% during the 4th quarter, according to the company in its most recent 13F ...

Fairfield Current
Celgene profit beats as psoriasis drug sales surge  Reuters

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher ...

Reuters
Celgene Stock Dips Despite Earnings, Sales Beat  Investor's Business Daily

Celgene earnings and sales topped expectations in the fourth quarter. The biotech also issued consensus-beating guidance. Celgene stock dipped a fraction.

Investor's Business Daily
Celgene Stock Rises After AbbVie CEO Rules Out a Big Deal  Barron's

Celgene stock (CELG) was higher Friday morning, rising $1.54 to $88 per share, after the CEO of AbbVie (ABBV) said on the company's earnings conference ...

Barron's
Celgene stock up 0.4% after earnings beat  MarketWatch

Shares of Celgene Corporation CELG, +2.23% rose 0.4% in premarket trade Thursday after the company announced fourth-quarter earnings that beat profit and ...

MarketWatch
Taking A Longer Viewpoint Of Celgene Corporation (CELG), Cisco Systems, Inc. (CSCO)  Post Analyst

Celgene Corporation (NASDAQ:CELG) recently had a high trading volume day. The volume for the company on 12-Feb-19 was recorded to be 8427339 ...

Post Analyst
'Strategic fit' with Bristol-Myers kept Celgene from casting wider net in deal negotiations  BioPharma Dive

Celgene approached only one other pharmaceutical company about the possibility of a deal as it negotiated an acquisition by Bristol-Myers Squibb, ultimately ...

BioPharma Dive
Contrasting of Celgene Corporation (CELG) and Wave Life Sciences Ltd. (NASDAQ:WVE)  The Hi New Ulm

As Biotechnology businesses, Celgene Corporation (NASDAQ:CELG) and Wave Life Sciences Ltd. (NASDAQ:WVE), are affected by contrast. This especially ...

The Hi New Ulm
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene  The Motley Fool

The drugmaker's fourth-quarter results were great. It's the prospects for future quarters that make the Celgene deal look appealing.

The Motley Fool
Celgene Corporation (CELG) CEO Mark Alles on Q4 2018 Results - Earnings Call Transcript  Seeking Alpha

Celgene Corporation (NASDAQ:CELG) Q4 2018 Earnings Conference Call January 31, 2019 09:00 AM ET Company Participants Nina Goworek - Executive ...

Seeking Alpha
Celgene down 3%  Seeking Alpha

Celgene ([[CELG]] -2.8%) is down on modestly higher volume in apparent to response to the potential involvement of activist investor Starboard Value via a.

Seeking Alpha
Cobblestone Capital Advisors LLC NY Lowers Position in Celgene Co. (CELG)  Fairfield Current

Cobblestone Capital Advisors LLC NY cut its stake in shares of Celgene Co. (NASDAQ:CELG) by 7.5% during the fourth quarter, according to its most recent ...

Fairfield Current
Here's How John Paulson Is Positioning His Celgene/Bristol Trade  Bloomberg

Billionaire John Paulson sees a 10 percent to 20 percent chance that Bristol-Myers Squibb Co. receives a takeover bid and he's positioning his Celgene Corp.

Bloomberg
Celgene Corporation (CELG), Viasat, Inc. (VSAT): Unadorned talk about these names  FinBulletin

Over the past 9 days, Celgene Corporation (NASDAQ: CELG) stock was observed to have a Historic Volatility of 20.05%. That figure, when expanded to look at ...

FinBulletin
1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)  The Motley Fool

At the start of the year, Gilead Sciences (NASDAQ:GILD) and Celgene (NASDAQ:CELG) were arguably the biggest value plays in the biotech industry. Gilead ...

The Motley Fool
Analysts said to Buy Healthcare Stock: Celgene Corporation (CELG)  Wall Street Morning

On Tuesday, Celgene Corporation (CELG) made the way into the market negative movers list with falling -0.88%. CELG reported a change of 1.07% over the ...

Wall Street Morning
Zurcher Kantonalbank Zurich Cantonalbank Buys 35,952 Shares of Celgene Co. (NASDAQ:CELG)  Fairfield Current

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Celgene Co. (NASDAQ:CELG) by 19.7% in the fourth quarter, according to its most recent ...

Fairfield Current
Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It  Seeking Alpha

The Bristol-Myers Squibb acquisition undervalues Celgene. Bristol-Myers would also be undervalued post-deal at current prices. I am inclined to keep the BMY ...

Seeking Alpha
Intra-Day Analysts Focus on Newmont Mining Corporation (NEM), Celgene Corporation (CELG)  MONReport

Newmont Mining Corporation (NYSE: NEM) experienced a high price of $33.81 with a low value of $33.28 at the end of the last trading session, which followed ...

MONReport
Two local biotechs sign deals with New Jersey’s Celgene  The Boston Globe

Two local biotech startups working on potential cancer treatments said Friday that they have made deals to collaborate with Celgene, the New Jersey-based ...

The Boston Globe
Celgene Buys More of This Biotech Stock  Barron's

The company disclosed this week that bought a boatload more of Acceleron Pharma stock. Celgene paid $30.4 million to buy 706206 more Acceleron shares on ...

Barron's
Comparing of Celgene Corporation (CELG) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)  The Hi New Ulm

Both Celgene Corporation (NASDAQ:CELG) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) are Biotechnology companies, competing one another.

The Hi New Ulm
Celgene Corporation (CELG) Q4 2018 Earnings Conference Call Transcript  Motley Fool

CELG earnings call for the period ending December 31, 2018.

Motley Fool
Celgene (CELG) Beats Q4 Earnings and Revenue Estimates  Zacks.com

Celgene (CELG) delivered earnings and revenue surprises of 3.02% and 1.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues ...

Zacks.com
The Bristol-Myers Celgene Deal, And Other Ideas  Seeking Alpha

This week's Idea Guide breaks down our coverage of the Bristol-Myers/Celgene deal. Our contributors express a mix of investor fatigue, excitement about the ...

Seeking Alpha
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup  Boston Business Journal

Atlas Venture-backed Kyn Therapeutics hopes to create drugs that reverse the effects of a metabolite called kynurenine, which cancer cells use to suppress the ...

Boston Business Journal
Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records  Endpoints News

Editor's Note: With Celgene showcasing its "continued commitment to work with partners" in twin deals today, we asked Chris Dokomajilar, founder and CEO of ...

Endpoints News
Celgene (CELG) Earnings Expected to Grow: Should You Buy?  Zacks.com

Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ...

Zacks.com
Celgene Corporation (CELG) and First Data Corporation (FDC) are About To Roar  NMSU Nеws

The shares of Celgene Corporation (NASDAQ:CELG) went up during the trading session by $1.96 on Monday, trading at $89.87. At the moment, the company ...

NMSU Nеws
Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis  PRNewswire

NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and ...

PRNewswire
How Celgene leaves a legacy of chutzpah in science and drug pricing  STAT

Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here.

STAT
American Financial Group Has Boosted Its Celgene (CELG) Position by $2.23 Million; As Jack Henry & Assoc (JKHY) Shares Declined, Shareholder Bright Rock Capital Management Lowered Holding by $384,000  The Hi New Ulm

American Financial Group Inc increased its stake in Celgene Corp (CELG) by 100% based on its latest 2018Q3 regulatory filing with the SEC. American ...

The Hi New Ulm
Celgene (CELG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release  Zacks.com

Celgene (CELG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ...

Zacks.com
Celgene Q4 2018 Earnings Preview  Seeking Alpha

Celgene (NASDAQ:CELG) is scheduled to announce Q4 earnings results on Thursday, January 31st, before market open. The consensus EPS Estimate is $2.32 ...

Seeking Alpha
Celgene enters $80m immuno-oncology partnership  BioPharma-Reporter.com

Celgene and Kyn Therapeutics enter a licensing agreement to develop Kyn's immuno-oncology pipeline for investigative therapies after Celgene was acquired ...

BioPharma-Reporter.com
Should You Buy At This Valuation? – Celgene Corporation (CELG), PDL BioPharma, Inc. (PDLI)  Post Analyst

Investors making a wish list of stocks to watch should take a look at Celgene Corporation (NASDAQ:CELG). The stock is offering a price-to-sales ratio of 4.02.

Post Analyst
Celgene signs brace of immuno-oncology deals with US biotechs  pharmaphorum

Despite a looming takeover by BMS, Celgene hasn't stopped making deals. It's just added two more partnerships for cancer immunotherapies.

pharmaphorum
Smaller groups await Bristol-Myers Squelgene fallout  Vantage

As the dust settles on Bristol-Myers Squibb's takeout of Celgene it is not just big pharma that is left wondering where it now stands. A slew of smaller companies ...

Vantage
Celgene (CELG) Shareholder First Interstate Bank Has Decreased Stake by $6.84 Million; Mcdonalds (MCD) Stock Value Rose While Smith Chas P & Associates Pa Cpas Boosted Its Stake  The Moveefy

First Interstate Bank decreased its stake in Celgene Corp (CELG) by 80.76% based on its latest 2018Q3 regulatory filing with the SEC. First Interstate Bank Smith ...

The Moveefy
Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results  Associated Press

SUMMIT, N.J.--(BUSINESS WIRE)--Jan 31, 2019--Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.

Associated Press
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices  FiercePharma

U.S. Representatives Peter Welch and Francis Rooney are urging the Federal Trade Commission and Department of Justice to take a close look at ...

FiercePharma
Oaktop Capital Management Ii LP Raised Celgene Com (CELG) Position; Newman Dignan & Sheerar Boosted International Business Machine (IBM) Stake by $313,020 as Stock Declined  The FinHeadLines

Oaktop Capital Management Ii Lp increased its stake in Celgene Corp Com (CELG) by 0.53% based on its latest 2018Q3 regulatory filing with the SEC. Oaktop ...

The FinHeadLines
Following the Consensus Analyst Rating on These Shares: Celgene Corporation (NASDAQ:CELG)  Martin Business Telegraph

Wall Street analysts have the ability to provide stock ratings for companies that they track. Based on analysts used by Zacks Research, the present average.

Martin Business Telegraph
My Top 2 Stocks For Young Investors: The Procter & Gamble Company (PG), Celgene Corporation (CELG)  GV Times

The stock of The Procter & Gamble Company (NYSE:PG) witnessed a 40.34% increase from the 52-week low price of $70.73. Their shares price went up by ...

GV Times
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink  Zacks.com

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

Zacks.com
An Extremely Compelling Valuation: Celgene Corporation (CELG), Teekay Tankers Ltd. (TNK)  NMSU Nеws

LOUGHLIN JAMES J, Director, sold 23,466 shares of the Celgene Corporation (NASDAQ:CELG) in an exchange that happened on February 7th. The stock was ...

NMSU Nеws
Adamas Pharma (ADMS) Stake Maintained by Dudley & Shanley Llc; Celgene (CELG) Shareholder American Financial Group Increased Its Position by $2.23 Million  The FinHeadLines

Dudley & Shanley Llc increased its stake in Adamas Pharma Inc. (ADMS) by 135.24% based on its latest 2018Q3 regulatory filing with the SEC. Dudley ...

The FinHeadLines
Celgene Corp (CELG) Chikou Pounds Ahead of the Tenkan  Martin Business Telegraph

Celgene Corp (CELG) are under the spotlight as the Chikou span line has crossed above the Tenkan line. The Ichimoku signals, indeed all Ichimoku.

Martin Business Telegraph
First Long Island Investors Has Increased Its Celgene Com (CELG) Holding by $623,000; Deere & Co (DE) Shareholder Acropolis Investment Management Has Trimmed Its Holding by $344,850 as Stock Price Declined  Thе Mоnіtоr

First Long Island Investors Llc increased its stake in Celgene Corp Com (CELG) by 10.82% based on its latest 2018Q3 regulatory filing with the SEC. First Long ...

Thе Mоnіtоr
As Celgene (CELG) Market Value Declined, Taylor Asset Management Has Boosted by $2.67 Million Its Holding; Express Scripts Hldg Co (ESRX) Share Price Rose While Mechanics Bank Trust Department Lowered Position by $2.13 Million  Port Courier

Taylor Asset Management Inc increased its stake in Celgene Corp (CELG) by 11.35% based on its latest 2018Q3 regulatory filing with the SEC. Taylor Asset ...

Port Courier
Take-Two, Las Vegas Sands, Unilever, Rio Tinto and Celgene highlighted as Zacks Bull and Bear of the Day  Nasdaq

For Immediate Release. Chicago, IL - February 12 2018 - Zacks Equity Research Take-Two Interactive Software, Inc. TTWO as the Bull of the Day, Las Vegas ...

Nasdaq
Placing the 0.063896 Earnings Yield in Perspective for Celgene Corporation (NasdaqGS:CELG)  LNR

The Earnings to Price yield of Celgene Corporation (NasdaqGS:CELG) is 0.045955. This is calculated by taking the earnings per share and dividing it by the.

LNR
Bouncing back from collapse: Celgene Corporation (CELG), Applied Materials, Inc. (AMAT)  FinBulletin

The share price of Celgene Corporation (NASDAQ: CELG) has taken quite a journey since the beginning of the year, with a year-to-date change of +25.78.

FinBulletin
AbbVie or Celgene: Which Is Controlling Its Expenses Better?  Market Realist

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an R&D (research and development) expense-to-sales ratio of 15.5% and an SG&A ...

Market Realist
Cls Investments Has Lifted Position in Celgene (CELG) as Valuation Declined; Folketrygdfondet Stake in Nokia (NOK) Raised as Stock Rose  The Moveefy

Cls Investments Llc increased its stake in Celgene Corp (CELG) by 6033.26% based on its latest 2018Q3 regulatory filing with the SEC. Cls Investments Llc ...

The Moveefy
Davidson DA & Company Has Decreased Celgene (CELG) Position as Valuation Declined; Schlumberger (SLB) Holder Portland Global Advisors Has Increased Position  The Hi New Ulm

Davidson D A & Company decreased its stake in Celgene Corp (CELG) by 40.84% based on its latest 2018Q3 regulatory filing with the SEC. Davidson D A ...

The Hi New Ulm
House Democrats question why N.J.-based Celgene charges so much for cancer drug  NJ.com

The House Oversight and Government Reform Committee has asked several pharmaceutical companies to explain why the costs of life-saving drugs keep going ...

NJ.com
Comparison of Celgene Corporation (CELG) and Clearside Biomedical Inc. (NASDAQ:CLSD)  Standard Recorder

Celgene Corporation (NASDAQ:CELG) and Clearside Biomedical Inc. (NASDAQ:CLSD) are two firms in the Biotechnology that compete against each other.

Standard Recorder
AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?  Market Realist

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

Market Realist
Executives On The Move: C-Suite Exits At Pfizer, Celgene And Sandoz, New President At MorphoSys  Scrip

C-suite moves at cancer biotech Geron Corp, EMD Serono Inc and Kiadis Pharma, while German biotech MorphoSys AG names David Trexler as its new ...

Scrip
Celgene (CELG) Shareholder State Of New Jersey Common Pension Fund D Has Boosted Its Position; Columbus Mckinnon NY (CMCO) Share Price Declined While Spitfire Capital Lowered Stake  Standard Recorder

State Of New Jersey Common Pension Fund D increased its stake in Celgene Corp (CELG) by 10.67% based on its latest 2018Q3 regulatory filing with the SEC.

Standard Recorder
Earnings Reaction History: Celgene Corporation, 45.5% Follow-Through Indicator, 3.8% Sensitive  Nasdaq

Expected Earnings Release: 01/31/2019, PremarketAvg. Extended-Hours Dollar Volume: $30712829Celgene Corporation ( CELG ) is due to issue its.

Nasdaq
Steady As She Goes: Stock update on Celgene Corp (CELG)  Martin Business Telegraph

After a recent check, we have noticed that the Chaikin Oscillator is above zero for Celgene Corp (CELG). Traders may be paying close attention to the stock and.

Martin Business Telegraph
LISTEN: CRISPR upheaval, Celgene's chutzpah, and canine genomics  STAT

In this episode of "The Readout LOUD," we pick apart the surprising news that the CEO of CRISPR-focused Editas Medicine is quitting her job come March.

STAT
Archford Capital Strategies Increases Stake in Microchip Technology Com (MCHP); Celgene (CELG) Holder Kidder Stephen W Lifted Stake by $418,300  Standard Recorder

Archford Capital Strategies Llc increased its stake in Microchip Technology Inc Com (MCHP) by 9065% based on its latest 2018Q3 regulatory filing with the SEC ...

Standard Recorder
Aleksandra Rizo Departs Celgene for Geron Chief Medical Post  Xconomy

Aleksandra Rizo has been appointed chief medical officer of Geron (NASDAQ: ]). Rizo comes to the Menlo Park, CA, drug developer from Summit, NJ-based.

Xconomy
Shelton Capital Management Reduced Holding in Celgene Co. (CELG)  BharataPress

Shelton Capital Management lessened its stake in Celgene Co. (NASDAQ:CELG) by 6.6% during the fourth quarter, HoldingsChannel.com reports. The firm ...

BharataPress
Celgene (NASDAQ:CELG) Issues FY 2019 Revenue Guidance  BharataPress

Celgene (NASDAQ:CELG) updated its FY 2019 earnings guidance on Thursday. The company provided EPS guidance of $10.60-10.80 for the period, ...

BharataPress
The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug  Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) ...

Benzinga
Bristol-Myers to buy Celgene in a $74 billion deal; Celgene shares surge  CNBC

Bristol-Myers Squibb is buying cancer drugmaker Celgene in a cash and stock deal valued at $74 billion, the companies announced Thursday. Under the ...

CNBC
Celgene Boosted the Price of Its Top Cancer Drug on the Same Day of Mega-Deal  Bloomberg

On the same day Celgene Corp. was announcing that it would be acquired by Bristol-Myers Squibb Co. in the biggest pharma deal ever, the company was also ...

Bloomberg
Celgene: Still Upside Left After Deal?  Seeking Alpha

Yesterday, Bristol-Myers Squibb announced a deal to acquire Celgene. This was biggest deal in the biotech sector in many, many years. While Celgene has ...

Seeking Alpha
Celgene's Positives Greatly Outweigh Negatives  Seeking Alpha

Celgene had some bad news, driving the stock to bargain prices in 2018. Ozanimod and Fedratinib applications to the FDA will be good signs. Multiple sales ...

Seeking Alpha
Is Beaten-Down Celgene Corporation a Buy Now?  Motley Fool

Celgene Corporation (NASDAQ:CELG) has been one of the worst-performing big biotech stocks of the past year even though the company has consistently ...

Motley Fool
Is Celgene Corporation a Buy?  The Motley Fool

Risks? Celgene has plenty of them. But the big biotech also looks like a bargain with tremendous growth prospects.

The Motley Fool
Celgene Stock Could Nearly Double, Analyst Says  Barron's

The biotech's shares look too cheap to Jefferies analyst Michael Yee, and he compares Celgene to Gilead in 2009.

Barron's
What Are Celgene's Key Sources of Revenue?  Forbes

Celgene (NASDAQ:CELG) is a global biopharmaceuticals company, which has recently entered into a merger agreement with Bristol-Myers Squibb in a deal ...

Forbes
Celgene's Stock Is Fairly Valued Even In Worst-Case Revlimid Scenario  Seeking Alpha

Celgene increased 2018 revenue expectations for the second time this year as strong growth continues. Celgene's rock-bottom Forward P/E of 6.59x and PEG ...

Seeking Alpha
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline  Zacks.com

Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

Zacks.com
What's in Store for Celgene Corp. (CELG) Q3 Earnings?  Yahoo Finance

Investors are looking forward to Revlimid's performance and other pipeline updates when Celgene (CELG) reports Q3 results on Oct 25.

Yahoo Finance
Celgene Co. (CELG) Expected to Announce Earnings of $2.32 Per Share  Baseball Daily News

Analysts expect Celgene Co. (NASDAQ:CELG) to announce earnings per share (EPS) of $2.32 for the current quarter, Zacks reports. Seven analysts have ...

Baseball Daily News
Better Buy: Celgene Corporation vs. Gilead Sciences  Motley Fool

Which big biotech is the better stock pick at the moment?

Motley Fool
Is The Bottom In For Celgene?  Seeking Alpha

CELG is a lot cheaper than this time last year. I look at the threat to Revlimid from generics manufacturers. I comment on the ongoing ozanimod story.

Seeking Alpha
Better Buy: Celgene Corporation vs. Merck & Co.  The Motley Fool

Two drug stocks diverged in a yellow wood. And sorry I could not buy both and be one investor, long I stood. My apologies to Robert Frost for butchering his ...

The Motley Fool
Celgene Beats and Raises, but It's All About the Pipeline  Motley Fool

Celgene (NASDAQ:CELG) continues to post solid revenue gains from its current drugs, but with generics of top-selling Revlimid slated to hit the market starting ...

Motley Fool
Celgene Doesn't Want To Be Left Out, Posts Promising JCAR017 Data  Seeking Alpha

Celgene announces positive preliminary data from its study treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic ...

Seeking Alpha
Better Buy: Celgene vs. Bristol-Myers Squibb  The Motley Fool

Both of these drugmaker stocks have stumbled recently, but which is the better stock right now?

The Motley Fool
Celgene: Money Will Flow Back  Seeking Alpha

Celgene dipped to multi-year lows of $70. The major culprit was biotech sector weakness causing money to flow away. The net payout yield has surged to 17%, ...

Seeking Alpha
Here's Why I'm Not Selling My Celgene Shares  Motley Fool

Celgene Corp. (NASDAQ:CELG) is one of biotech's largest companies, but that hasn't kept shares from falling in the past year because of disappointments and ...

Motley Fool
Celgene: Investment Thesis Still Not Compelling  Seeking Alpha

Celgene is traded at multi-year lows due to upcoming Revlimid loss of exclusivity in 2022. Celgene argues that upcoming new agents will substitute Revlimid ...

Seeking Alpha
Celgene Corporation (CELG) Presents at Credit Suisse 27th Annual Healthcare Conference (Transcript)  Seeking Alpha

Celgene Corporation (NASDAQ:CELG) Credit Suisse 27th Annual Healthcare Conference Call November 14, 2018 10:45 AM ET Executives Terrie Curran ...

Seeking Alpha
 

Celgene Videos

Bristol-Myers and Celgene CEOs talk acquisition deal
16:29:14
Bristol-Myers and Celgene CEOs talk acquisition deal
Bristol-Myers, Celgene deal in focus
17:56:12
Bristol-Myers, Celgene deal in focus
Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene
16:31:15
Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene
Celgene deal is a 'bold' move: Fmr. Medtronic CEO
18:32:59
Celgene deal is a 'bold' move: Fmr. Medtronic CEO
Jefferies: Buy Celgene, lowest P/E in history
19:18:24
Jefferies: Buy Celgene, lowest P/E in history
Bristol-Myers' Celgene acquisition is the start of pharmaceutical industry mergers: analyst
17:08:42
Bristol-Myers' Celgene acquisition is the start of pharmaceutical industry mergers: analyst
Celgene Stock - Is Celgene Stock a Buy Today?
18:30:00
Celgene Stock - Is Celgene Stock a Buy Today?
This is a good deal for Celgene: Bernstein analyst
19:16:36
This is a good deal for Celgene: Bernstein analyst
Celgene Corporation (CELG) Stock Analysis 2018
05:24:16
Celgene Corporation (CELG) Stock Analysis 2018
Why Did the Stock Market Shun Bristol-Myers $74B Deal for Celgene?
16:28:24
Why Did the Stock Market Shun Bristol-Myers $74B Deal for Celgene?
 

Celgene Images

Getting Greener - Celgene
Getting Greener - Celgene
Celgene : Custom Exhibits
Celgene : Custom Exhibits
Celgene: A Global Biopharmaceutical Company Committed to ...
Celgene: A Global Biopharmaceutical Company Committed to ...
Celgene and Agios win FDA approval for targeted AML drug ...
Celgene and Agios win FDA approval for targeted AML drug ...
Financing Cures: Health Care Payers - Celgene
Financing Cures: Health Care Payers - Celgene
J&J joins Pfizer, Celgene, Biogen and more in DOJ's ...
J&J joins Pfizer, Celgene, Biogen and more in DOJ's ...
SCIENCE & TECHNOLOGY - Sweetwater Construction Corp ...
SCIENCE & TECHNOLOGY - Sweetwater Construction Corp ...
Revlimid - FDA prescribing information, side effects and uses
Revlimid - FDA prescribing information, side effects and uses
Epigenetic modulators as therapeutic targets in prostate ...
Epigenetic modulators as therapeutic targets in prostate ...
[VIDEO] La Défense : KPMG dévoile ses nouveaux espaces de ...
[VIDEO] La Défense : KPMG dévoile ses nouveaux espaces de ...
 

Celgene WebSites

 

Celgene Wiki

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.